Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
RenovoRx, Inc. Common Stock is a biotechnology business based in the US. RenovoRx shares (RNXT) are listed on the NASDAQ and all prices are listed in US Dollars. RenovoRx employs 8 staff and has a market cap (total outstanding shares value) of USD$49.4 million.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|Latest market close||$5.88|
|52-week range||$5.37 - $16.74|
|50-day moving average||$7.57|
|200-day moving average||$7.56|
|Wall St. target price||N/A|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.98|
Note: The dollar amounts in the table below are in Canadian dollars.
|1 week (2021-10-15)||-1.67%|
|1 month (2021-09-22)||-19.89%|
|3 months (2021-07-18)||N/A|
|6 months (2021-04-18)||N/A|
|1 year (2020-10-18)||N/A|
|2 years (2019-10-18)||N/A|
|3 years (2018-10-18)||N/A|
|5 years (2016-10-18)||N/A|
|Gross profit TTM||$0|
|Return on assets TTM||0%|
|Return on equity TTM||0%|
|Market capitalisation||$49.4 million|
TTM: trailing 12 months
There are currently 60,508 RenovoRx shares held short by investors – that's known as RenovoRx's "short interest". This figure is 12% up from 54,044 last month.
There are a few different ways that this level of interest in shorting RenovoRx shares can be evaluated.
RenovoRx's "short interest ratio" (SIR) is the quantity of RenovoRx shares currently shorted divided by the average quantity of RenovoRx shares traded daily (recently around 3.0 million). RenovoRx's SIR currently stands at 0.02. In other words for every 100,000 RenovoRx shares traded daily on the market, roughly 20 shares are currently held short.
To gain some more context, you can compare RenovoRx's short interest ratio against those of similar companies.
However RenovoRx's short interest can also be evaluated against the total number of RenovoRx shares, or, against the total number of tradable RenovoRx shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case RenovoRx's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 RenovoRx shares in existence, roughly 10 shares are currently held short) or 0.0364% of the tradable shares (for every 100,000 tradable RenovoRx shares, roughly 36 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against RenovoRx.
We're not expecting RenovoRx to pay a dividend over the next 12 months.
RenovoRx, Inc. , a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Los Altos, California. .
Stock trading doesn’t have to be expensive. Using Finder’s proprietary algorithm, we’ve identified the best cheap Canadian and US stocks to buy now.Read more…
Steps to owning and managing Cue Health stocks, with 24-hour and historical pricing before you buy.Read more…
Steps to owning and managing ARBK stock, with 24-hour and historical pricing before you buy.Read more…
Steps to owning and managing ENGH stock, with 24-hour and historical pricing before you buy.
Everything we know about the Paragon 28, Inc. IPO, plus information on how to buy in.
Everything we know about the Winc IPO, plus information on how to buy in.
Everything we know about the Ventyx Biosciences IPO, plus information on how to buy in.
Everything we know about the The Vita Coco Company IPO, plus information on how to buy in.
Everything we know about the Portillo’s IPO, plus information on how to buy in.
Everything we know about the P10 IPO, plus information on how to buy in.
Everything we know about the Minerva Surgical IPO, plus information on how to buy in.
Everything we know about the Aris Water Solutions IPO, plus information on how to buy in.
Everything we know about the Enfusion IPO, plus information on how to buy in.
You must be logged in to post a comment.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.